Notice of Correction of Eligibility for RFA-CA-13-012 "NCI Community Oncology Research Program (NCORP) Research Bases (UM1)
Notice Number: NOT-CA-14-012
Key Dates
Release Date: November 20, 2013
Related Announcements
RFA-CA-13-012
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to clarify the eligibility requirements for RFA-CA-13-012, entitled "NCI Community Oncology Research Program (NCORP) Research Bases (UM1).”
Specifically, the following corrections are made.
Section III.1 Eligible Applicants
Eligible Organizations
Currently reads:
Additional Eligibility provisions:
- Applicant institutions must be appropriate leading institutions with comprehensive expertise in cancer clinical trials, such as institutions that are cancer foundations, healthcare research organizations (including sites of Clinical Trials Cooperative Groups or NCTN Group Operations Centers), NCI-designated Cancer Centers, or integrated healthcare systems.
- Applicant institutions must have an established organizational structure for the design and conduct of multi-center cancer prevention, control and screening/post-treatment surveillance clinical trials and cancer care delivery research.
Institutions not eligible to apply include:
- Institutions that are clinical sites for the NCI Clinical Trials Cooperative Groups or are applicants for the NCTN Lead Academic Site award (or awardees of that NCTN component).
Corrected to read:
Additional Eligibility provisions:
- Applicant institutions must be appropriate leading institutions with comprehensive expertise in cancer clinical trials, such as institutions that are cancer foundations, healthcare research organizations (including sites of Clinical Trials Cooperative Groups or NCTN Group Operations Centers or Community Clinical Oncology Research Bases), NCI-designated Cancer Centers, or integrated healthcare systems.
- Applicant institutions must have an established organizational structure for the design and conduct of multi-center cancer prevention, control and screening/post-treatment surveillance clinical trials and cancer care delivery research.
Section III.1 Eligible Applicants
Foreign Institutions
Currently reads:
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Corrected to read:
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
All other aspects of the FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Worta McCaskill-Stevens, M.D., M.S.
National Cancer Institute (NCI)
Telephone: 240-276-7050
Email:
mccaskiw@mail.nih.gov